SCHEMBL4355850

SCHEMBL4355850

CCCCCNC(=S)Nc1ccc(F)c(F)c1O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.58
EPHX2 P34913 1/20 0.54
KMT2A Q03164 6/20 0.52
MEN1 O00255 4/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 3/20 0.48
ALOX12 P18054 2/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
LMNA P02545 7/20 0.47
HTT P42858 6/20 0.44
RECQL P46063 1/20 0.43
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.41
APOBEC3G Q9HC16 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350067 0.83 SMN1; SMN2 (0.70) SMN1; SMN2EPHX2KMT2AMEN1ALDH1A1
SCHEMBL27782813 0.79 SMN1; SMN2 (0.76) SMN1; SMN2KMT2AMEN1ALDH1A1HPGD
SCHEMBL7143587 0.78 SMN1; SMN2 (0.62) SMN1; SMN2EPHX2KMT2AMEN1ALDH1A1
SCHEMBL16320691 0.77 SMN1; SMN2 (0.89) SMN1; SMN2KMT2AMEN1ALDH1A1CYP1A2
SCHEMBL4349397 0.76 SMN1; SMN2 (0.52) SMN1; SMN2EPHX2KMT2AMEN1ALDH1A1
SCHEMBL4354051 0.75 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AMEN1ALDH1A1HPGD
SCHEMBL4356036 0.75 HTT (0.60) SMN1; SMN2KMT2AMEN1ALDH1A1ALOX12
SCHEMBL4348984 0.74 SMN1; SMN2 (0.50) SMN1; SMN2HPGDLMNAHTTRECQL
SCHEMBL21815078 0.74 GAA (0.47) SMN1; SMN2KMT2AMEN1HPGDALOX12
SCHEMBL4351491 0.73 ALOX12 (0.59) SMN1; SMN2KMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885EPHX2 769/4885KMT2A 2096/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885EPHX2 627/4885KMT2A 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.